Page 150 - Human Use News Today

LONDON (dpa-AFX) - British drug major AstraZeneca Plc.'s (AZN, AZN.L) long-acting antibody combination Evusheld has been recommended for marketing authorisation in the European Union for the pre-exposure

– CHMP recommendation follows September 2021 U.S. FDA approval of CABOMETYX in this setting – ... | March 25, 2022

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease

CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2 Graft-versus-host disease (GvHD)

Ciltacabtagene autoleucel, if approved by the European Commission , will be Legend Biotech’s first EC-approved product ... | March 25, 2022

BASEL (dpa-AFX) - Novartis (NVS) announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the European Commission

Opinion Granted Based on Positive Results From Phase 3 KEYNOTE-826 Trial Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency's Committee

CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2 Graft-versus-host disease is a... | March 25, 2022

(RTTNews) - Novartis (NVS) said Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has a...